TNFRSF17 and plasma cell myeloma: Based upon the selection of a highly active and specific BCMA-targeting CAR clone described here, we opened a clinical trial (NCT02546167) that is testing the safety and efficacy of autologous CART cells expressing BCMA CAR Clone 10 in patients with relapsed and/or refractory multiple myeloma.